Why Cortexyme Thinks It Could Be Next In The Mega Alzheimer's Drug Market

Why Cortexyme Thinks It Could Be Next In The Mega Alzheimer's Drug Market

The next donnybrook in Alzheimer's disease is looming. Biogen gained the first approval, and a slew of biotech stocks are now lining up.